PD-L1 expression in pleomorphic, spindle cell and giant cell carcinoma of the lung is related to TTF-1, p40 expression and might indicate a worse prognosis

被引:47
|
作者
Yvorel, Violaine [1 ]
Patoir, Arnaud [2 ]
Casteillo, Francois [1 ]
Tissot, Claire [3 ]
Fournel, Pierre [4 ]
Stachowicz, Marie-Laure [1 ]
Karpathiou, Georgia [1 ]
Tiffet, Olivier [2 ]
Peoc'h, Michel [1 ]
Forest, Fabien [1 ]
机构
[1] Univ Hosp St Etienne, North Hosp, Dept Pathol, St Etienne, France
[2] Univ Hosp St Etienne, North Hosp, Dept Thorac Surg, St Etienne, France
[3] Univ Hosp St Etienne, North Hosp, Dept Pneumol, St Etienne, France
[4] Lucien Neuwirth Canc Inst, Dept Oncol, St Priest En Jarez, France
来源
PLOS ONE | 2017年 / 12卷 / 07期
关键词
DEATH LIGAND-1 PD-L1; SHOW HIGH-LEVELS; CANCER;
D O I
10.1371/journal.pone.0180346
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Lung sarcomatoid carcinoma of the lung is a rare tumor with a poor prognosis. More than 90% of them are pleomorphic, spindle cell and giant cell carcinoma (PSCGCC). This rare subtype of lung cancer is thought to be more resistant to chemotherapy, and a small subset of them seems to exhibit targetable mutations. Immunotherapy against PD1/PDL-1 is a new emerging treatment, and might be of interest in PSGSCC because they frequently express PD-L1. The aim of our work is to evaluate PD1 and PDL-1 expression in a surgical series of lung PSCGCC and their relationship with morphological and immunohistochemical parameters and prognosis. Thirty-six patients who underwent surgical resection of a PSGSCC were included. PD-L1 (E1L3N) expression on tumor cells and PD1 (NAT105) expression by tumor infiltrating lymphocytes (TILs) were performed by immunohistochemistry. Results were compared to immunohistochemistry tests of TTF1, Napsin A, p40 and to molecular study of EGFR, KRAS, BRAF and HER2. Seventy-five % of PSCGCC were considered as positive for PD-L1. PD-L1 expression in PSGSCC is associated with TTF-1 and/or Napsin A expression (47.2%, p = 0.039). Few p40 positive PSCGCC expressed PD-L1 (8.3%, p = 0.013). PD1 expression was not related to TTF-1 and/or Napsin A expression (p = 0.47), p40 expression (p = 0.68) or survival (p = 0.14). PD-L1 or PD1 expression were not related to the age, gender, pT, pN, stage, visceral pleura invasion, histopathological subtype, the presence of giant cell component, the predominance of sarcomatoid component, and the presence of EGFR or BRAF or HER2 or PIK3CA mutation (p> 0.05). PD-L1 expression was correlated with a worse overall survival in PSCGCC (p = 0.045). PD-L1 expression is frequent in PSCGCC and might be associated with the expression of adenocarcinoma markers (TTF-1, Napsin A) or the lack of expression of squamous cell carcinoma marker (p40).
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Programmed death-ligand 1 (PD-L1) expression in pleomorphic carcinoma of the lung
    Imanishi, Naoko
    Hirai, Ayako
    Yoneda, Kazue
    Shimajiri, Shohei
    Kuwata, Taiji
    Tashima, Yuko
    Takeuchi, Masahiro
    Iwai, Yoshiko
    Ichiki, Yoshinobu
    Tanaka, Fumihiro
    JOURNAL OF SURGICAL ONCOLOGY, 2018, 117 (07) : 1563 - 1569
  • [2] PD-L1 expression in large cell neuroendocrine carcinoma of the lung
    Eichhorn, F.
    Harms, A.
    Warth, A.
    Muley, T.
    Winter, H.
    Eichhorn, M. E.
    LUNG CANCER, 2018, 118 : 76 - 82
  • [3] PD-L1 Expression is Associated With Poor Prognosis in Renal Cell Carcinoma
    Carlsson, Jessica
    Sundqvist, Pernilla
    Kosuta, Vezira
    Falt, Anna
    Giunchi, Francesca
    Fiorentino, Michelangelo
    Davidsson, Sabina
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2020, 28 (03) : 213 - 220
  • [4] A High PD-L1 Expression in Pulmonary Pleomorphic Carcinoma Correlates with Parietal-pleural Invasion and Might Predict a Poor Prognosis
    Naito, Maiko
    Tamiya, Akihiro
    Takeda, Maiko
    Taniguchi, Yoshihiko
    Saijo, Nobuhiko
    Naoki, Yoko
    Okishio, Kyoichi
    Yoon, Hyungeun
    Kasai, Takahiko
    Matsumura, Akihide
    Atagi, Shinji
    INTERNAL MEDICINE, 2019, 58 (07) : 921 - 927
  • [5] PD-L1 Protein Expression and Gene Amplification Correlate with the Clinicopathological Characteristics and Prognosis of Lung Squamous Cell Carcinoma
    Chen, Zhenwen
    Zhao, Ning
    Wang, Qi
    Xi, Yanfeng
    Tian, Xiaoai
    Wu, Huiwen
    Xu, Yirong
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 6365 - 6375
  • [6] Clinicopathological Characteristics and Prognosis Analysis of Lung Carcinoma With p40/TTF1 Coexpression and Lung Adenosquamous Carcinoma: Lung Carcinoma With p40/TTF1 Coexpression Is a Rare Tumor With High Metastatic Potential
    Gao, Rui
    Zhang, Xi
    Chen, Xiaoyan
    Chen, Xin
    Jin, Long
    Zheng, Huawei
    Yu, Xunbin
    INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY, 2024, 32 (07) : 1286 - 1291
  • [7] Association of Programmed Death 1 Protein Ligand (PD-L1) Expression With Prognosis in Merkel Cell Carcinoma
    Hanna, Glenn J.
    Kacew, Alec J.
    Tanguturi, Anusha R.
    Grote, Hans J.
    Vergara, Victoria
    Brunkhorst, Beatrice
    Rabinowits, Guilherme
    Thakuria, Manisha
    LeBoeuf, Nicole R.
    Ihling, Christian
    DeCaprio, James A.
    Lorch, Jochen H.
    FRONTIERS IN MEDICINE, 2020, 7
  • [8] Evaluation of PD-1 and PD-L1 expression in canine urothelial carcinoma cell lines
    Pinard, Christopher J.
    Hocker, Samuel E.
    Poon, Andrew C.
    Inkol, Jordon M.
    Matsuyama, Arata
    Wood, R. Darren
    Wood, Geoffrey A.
    Woods, J. Paul
    Mutsaers, Anthony J.
    VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 2022, 243
  • [9] PD-1/PD-L1 expression in chromophobe renal cell carcinoma: An immunological exception?
    Erlmeier, Franziska
    Hartmann, Arndt
    Autenrieth, Michael
    Wiedemann, Max
    Ivanyi, Philipp
    Steffens, Sandra
    Weichert, Wilko
    MEDICAL ONCOLOGY, 2016, 33 (11)
  • [10] Determination of the Expression of PD-L1 in the Morphologic Spectrum of Renal Cell Carcinoma
    Walter, Beatriz
    Gil, Sara
    Xu Naizhen
    Kruhlak, Michael J.
    Linehan, W. Marston
    Srinivasan, Ramaprasad
    Merino, Maria J.
    JOURNAL OF CANCER, 2020, 11 (12): : 3596 - 3603